ATE256186T1 - Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten - Google Patents
Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheitenInfo
- Publication number
- ATE256186T1 ATE256186T1 AT97940771T AT97940771T ATE256186T1 AT E256186 T1 ATE256186 T1 AT E256186T1 AT 97940771 T AT97940771 T AT 97940771T AT 97940771 T AT97940771 T AT 97940771T AT E256186 T1 ATE256186 T1 AT E256186T1
- Authority
- AT
- Austria
- Prior art keywords
- vegf145
- derivatives
- novel
- protein products
- vegf
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2553796P | 1996-09-06 | 1996-09-06 | |
US08/784,551 US6013780A (en) | 1996-09-06 | 1997-01-21 | VEGF145 expression vectors |
PCT/US1997/015471 WO1998010071A1 (en) | 1996-09-06 | 1997-09-04 | Angiogenic factor and use thereof in treating cardiovascular disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE256186T1 true ATE256186T1 (de) | 2003-12-15 |
Family
ID=26699889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97940771T ATE256186T1 (de) | 1996-09-06 | 1997-09-04 | Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten |
Country Status (15)
Country | Link |
---|---|
US (3) | US6013780A (de) |
EP (1) | EP0925360B1 (de) |
JP (1) | JP2001500728A (de) |
KR (1) | KR20000068506A (de) |
CN (1) | CN1236390A (de) |
AT (1) | ATE256186T1 (de) |
AU (1) | AU737898B2 (de) |
CA (1) | CA2265252C (de) |
DE (1) | DE69726741T2 (de) |
EA (1) | EA004646B1 (de) |
ES (1) | ES2212127T3 (de) |
HK (1) | HK1020756A1 (de) |
IL (1) | IL128727A (de) |
NZ (1) | NZ334508A (de) |
WO (1) | WO1998010071A1 (de) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238673B2 (en) | 1989-03-31 | 2007-07-03 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US20040071637A1 (en) * | 1993-04-27 | 2004-04-15 | Elia James P. | Method for repairing a damaged portion of a human organ |
US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
US20030165467A1 (en) * | 1997-01-21 | 2003-09-04 | Technion Research & Development Co., Ltd. | Angiogenic factor and use thereof in treating cardiovascular disease |
US6485942B1 (en) | 1997-02-14 | 2002-11-26 | Genentech, Inc. | Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production |
US6376471B1 (en) * | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
AU767662B2 (en) * | 1998-02-06 | 2003-11-20 | Collateral Therapeutics, Inc. | Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
JP4769929B2 (ja) * | 1998-10-26 | 2011-09-07 | ベジェニクス ピーティーワイ リミテッド | Vegf−cまたはvegf−d遺伝子またはタンパク質を用いた再狭窄の予防 |
US6783953B1 (en) | 1998-12-22 | 2004-08-31 | Janssen Pharmaceutica N.V. | Vascular endothelial growth factor-X |
US20040131601A1 (en) * | 2000-03-30 | 2004-07-08 | Foundry Networks, Inc., A Delaward Corporation | Injection of bone marrow-derived cells and medium for angiogenesis |
US7097832B1 (en) | 1999-03-30 | 2006-08-29 | Myocardial Therapeutics, Inc. | Intramyocardial injection of autologous bone marrow |
US7125856B1 (en) | 1999-04-15 | 2006-10-24 | St. Elizabeth's Medical Center Of Boston, Inc. | Angiogenic growth factors for treatment of peripheral neuropathy |
WO2000071713A1 (en) | 1999-05-20 | 2000-11-30 | Scios Inc. | Vascular endothelial growth factor variants |
AU5026100A (en) * | 1999-05-20 | 2000-12-12 | Scios Inc. | Vascular endothelial growth factor dimers |
US6899731B2 (en) * | 1999-12-30 | 2005-05-31 | Boston Scientific Scimed, Inc. | Controlled delivery of therapeutic agents by insertable medical devices |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US8460367B2 (en) | 2000-03-15 | 2013-06-11 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
CA2400319C (en) * | 2000-03-15 | 2008-09-16 | Orbus Medical Technologies Inc. | Coating that promotes endothelial cell adherence |
PT2277528E (pt) | 2000-04-12 | 2015-02-05 | Life Sciences Res Partners Vzw | Uso de vegf e homólogos para tratar doenças do neurónio |
EP1294407A2 (de) * | 2000-06-30 | 2003-03-26 | Collateral Therapeutics | Zweirekombinante enthaltende zusammensetzungen zur gentherapie und verfahren zur herstellung |
WO2002014487A2 (en) * | 2000-08-17 | 2002-02-21 | Keiya Ozawa | Adeno-associated virus-mediated delivery of angiogenic factors |
US6953560B1 (en) | 2000-09-28 | 2005-10-11 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US6716444B1 (en) | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
AU2884102A (en) | 2000-12-07 | 2002-06-18 | Sangamo Biosciences Inc | Regulation of angiogenesis with zinc finger proteins |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
US6663662B2 (en) * | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
US20050142130A1 (en) * | 2001-01-04 | 2005-06-30 | Roks Antonius J.M. | Use of angiotensin-(1-7) for preventing and/or reducing the formation of neointima |
DK1399484T3 (da) * | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
EP2311960A3 (de) | 2001-08-29 | 2011-06-01 | Genentech, Inc. | Bv8-Nukleinsäuren und Polypeptide mit mitogener Aktivität |
WO2003020215A2 (en) * | 2001-08-29 | 2003-03-13 | Regenerx Biopharmaceuticals, Inc. | Methods of treating mycocardial event related coditions with thymosin beta 4 |
US6753071B1 (en) * | 2001-09-27 | 2004-06-22 | Advanced Cardiovascular Systems, Inc. | Rate-reducing membrane for release of an agent |
US20050075298A1 (en) * | 2002-01-31 | 2005-04-07 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
CA2487410C (en) * | 2002-05-30 | 2015-03-24 | Myocardial Therapeutics, Inc. | Intramyocardial injection of autologous bone marrow |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
JP2006512895A (ja) * | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
CA2508631A1 (en) * | 2002-12-09 | 2004-06-24 | Toolgen, Inc. | Regulatory zinc finger proteins |
AU2003285758A1 (en) * | 2002-12-17 | 2004-07-09 | Technion Research And Development Foundation Ltd. | A vegf variant that lacks vegfr-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis |
JP2006523090A (ja) * | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
US7632810B2 (en) | 2003-03-12 | 2009-12-15 | Genentech, Inc. | Compositions with hematopoietic and immune activity |
EP1877065A4 (de) * | 2005-04-12 | 2010-12-22 | Intradigm Corp | Zusammensetzung und verfahren mit rnai-therapeutika zur behandlung von krebs und anderen gefässneubildungserkrankungen |
US7893244B2 (en) * | 2005-04-12 | 2011-02-22 | Intradigm Corporation | Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases |
KR100772424B1 (ko) * | 2005-08-05 | 2007-11-01 | 박기랑 | ⅤEGF-A,ⅤEGF-B,및 ⅤEGF-C의 안티센스 cDNA를 함유하는 재조합 아데노-연관 바이러스 및 ⅤEGFR 트렁케이티드 솔루블 cDNA를 함유하는 재조합 아데노-연관 바이러스를 포함하는 암의 유전자 치료제 |
EA200801170A1 (ru) * | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы неконкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
BRPI0812398A2 (pt) * | 2007-06-06 | 2019-09-24 | Domantis Ltd | domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão |
EP2349371B1 (de) * | 2008-10-07 | 2013-12-04 | Boston Scientific Scimed, Inc. | Medizinische vorrichtungen zur freisetzung von wirkstoffen in körperlumen |
CN110760542B (zh) * | 2019-11-18 | 2022-07-26 | 天津大学 | 一种共表达znf580和vegf165双基因的质粒及应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5240848A (en) * | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5288846A (en) * | 1990-10-19 | 1994-02-22 | The General Hospital Corporation | Cell specific gene regulators |
US5298422A (en) * | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
US5318957A (en) * | 1992-09-02 | 1994-06-07 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating angiogenesis |
ATE206756T1 (de) * | 1994-07-20 | 2001-10-15 | Kyowa Hakko Kogyo Kk | Verfahren zur herstellung von stabilisierter getrockeneter carboxyesterase |
US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
US5652225A (en) * | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
US5792453A (en) * | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
-
1997
- 1997-01-21 US US08/784,551 patent/US6013780A/en not_active Expired - Lifetime
- 1997-09-04 WO PCT/US1997/015471 patent/WO1998010071A1/en not_active Application Discontinuation
- 1997-09-04 AU AU42471/97A patent/AU737898B2/en not_active Ceased
- 1997-09-04 CA CA002265252A patent/CA2265252C/en not_active Expired - Fee Related
- 1997-09-04 ES ES97940771T patent/ES2212127T3/es not_active Expired - Lifetime
- 1997-09-04 KR KR1019997001920A patent/KR20000068506A/ko not_active Application Discontinuation
- 1997-09-04 EA EA199900262A patent/EA004646B1/ru not_active IP Right Cessation
- 1997-09-04 CN CN97199495A patent/CN1236390A/zh active Pending
- 1997-09-04 IL IL128727A patent/IL128727A/en not_active IP Right Cessation
- 1997-09-04 AT AT97940771T patent/ATE256186T1/de not_active IP Right Cessation
- 1997-09-04 JP JP10512834A patent/JP2001500728A/ja not_active Ceased
- 1997-09-04 EP EP97940771A patent/EP0925360B1/de not_active Expired - Lifetime
- 1997-09-04 DE DE69726741T patent/DE69726741T2/de not_active Expired - Fee Related
- 1997-09-04 NZ NZ334508A patent/NZ334508A/en unknown
-
1998
- 1998-03-11 US US09/037,983 patent/US6583276B1/en not_active Expired - Lifetime
-
1999
- 1999-10-28 US US09/428,909 patent/US6589782B1/en not_active Expired - Lifetime
- 1999-12-17 HK HK99105958A patent/HK1020756A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1236390A (zh) | 1999-11-24 |
ES2212127T3 (es) | 2004-07-16 |
US6013780A (en) | 2000-01-11 |
JP2001500728A (ja) | 2001-01-23 |
KR20000068506A (ko) | 2000-11-25 |
HK1020756A1 (en) | 2000-05-19 |
CA2265252A1 (en) | 1998-03-12 |
IL128727A (en) | 2007-06-17 |
CA2265252C (en) | 2005-04-19 |
EP0925360A1 (de) | 1999-06-30 |
US6589782B1 (en) | 2003-07-08 |
DE69726741T2 (de) | 2004-09-30 |
AU737898B2 (en) | 2001-09-06 |
EP0925360B1 (de) | 2003-12-10 |
EA004646B1 (ru) | 2004-06-24 |
EA199900262A1 (ru) | 1999-10-28 |
US6583276B1 (en) | 2003-06-24 |
NZ334508A (en) | 2001-03-30 |
AU4247197A (en) | 1998-03-26 |
IL128727A0 (en) | 2005-11-20 |
WO1998010071A1 (en) | 1998-03-12 |
DE69726741D1 (de) | 2004-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE256186T1 (de) | Verwendungen von angiogenischer factor vegf145 in der behandlung von kardiovaskulaeren krankheiten | |
PT749317E (pt) | Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade | |
WO1999040197A3 (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf | |
TR199902818T2 (xx) | Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler. | |
DE69328685T2 (de) | Verfahren zur inaktivierung von bakterien in blutpräparaten mit hilfe von methoxypsoralen | |
DE69937294D1 (de) | Von cyclophilin b abstammende tumorantigen-peptide | |
YU46097A (sh) | Nova klasa estara i njihove farmaceutske smeše | |
JP2002531055A5 (de) | ||
DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
NO971341L (no) | Promoter for reseptor tyrosinkinase TIE | |
FR2805821B1 (fr) | Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires | |
Leonard et al. | Growth factor functionalized biomaterial for drug delivery and tissue regeneration | |
ATE88500T1 (de) | Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel. | |
ATE433461T1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
Bodnar et al. | Pericytes reduce inflammation and collagen deposition in acute wounds | |
DE69832798D1 (de) | Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen. | |
DE69510356D1 (de) | Anti-sickling beta-globin,zusammensetzung und verfahren zur behandlung von sichelzellanämie | |
ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
ES2174103T3 (es) | Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano. | |
WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
DE69712182T2 (de) | Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises | |
ATE239749T1 (de) | Phosphor-enthaltende dendrimere als transfektionsagente | |
Becker et al. | Effect of the flavonoid (+) cyanidanol-3 on procollagen biosynthesis and transport in normal and ataxia telangiectasia cultured skin fibroblasts | |
JPH0720995B2 (ja) | 牛脾臓由来の細胞増殖促進物質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0925360 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |